(Q33405170)

26 July 2017

title

"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center (English)

1 reference

26 July 2017

1 reference

0 references

5

1 reference

26 July 2017

Norbert Galldiks

1

0 references

Tobias Blau

series ordinal

3

object named as

Tobias Blau

1 reference

26 July 2017

Theresa Berhorn

2

1 reference

26 July 2017

Veronika Dunkl

series ordinal

4

1 reference

26 July 2017

Michael Schroeter

series ordinal

6

1 reference

26 July 2017

publication date

9 January 2013

1 reference

Journal of Neuro-Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

112

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

209-215

1 reference

Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Rechallenge with temozolomide in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Long-term survival with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1048-Z

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23299464

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-013-1048-Z

1 reference

Dimensions Publication ID

26 July 2017

1000439873

0 references

Fatcat ID

release_yuuztpcvpvdvpb5y76cinmq7di

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yuuztpcvpvdvpb5y76cinmq7di

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference